OTCMKTS:HKMPF Hikma Pharmaceuticals (HKMPF) Stock Price, News & Analysis → Bill Clinton Backing Biden Replacement??? (From The Freeport Society) (Ad) Free HKMPF Stock Alerts $24.50 0.00 (0.00%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$24.50▼$24.5050-Day Range$22.33▼$24.5052-Week Range$21.28▼$27.15VolumeN/AAverage Volume85 shsMarket Capitalization$5.40 billionP/E RatioN/ADividend Yield3.84%Price TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartDividendHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartDividendHeadlinesShort Interest Get Hikma Pharmaceuticals alerts: Email Address Ad Huge AlertsWhy Is Gold On a MASSIVE rally? Gold has been on a tear this year. The yellow metal has hit an all-time high of $2,4231.29 recently and the rally could be far from over. From central banks to even Costco customers, it seems everyone is buying gold these days. With Wall Street watching the gold space carefully, now is a perfect time to pay attention to this stock.This Little known Company is a uniquely structured for profit About Hikma Pharmaceuticals Stock (OTCMKTS:HKMPF)Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.Read More HKMPF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HKMPF Stock News HeadlinesApril 29, 2024 | markets.businessinsider.comCollegium Pharma Partners With Hikma For Authorized Generics Of Nucynta In USMarch 20, 2024 | msn.comHikma Pharmaceuticals PLC goes ex dividend tomorrowMarch 18, 2024 | finance.yahoo.comOptimism around Hikma Pharmaceuticals (LON:HIK) delivering new earnings growth may be shrinking as stock declines 3.3% this past weekFebruary 27, 2024 | finance.yahoo.comHikma Pharmaceuticals PLC (HKMPF)February 22, 2024 | msn.comDrugmaker Hikma expects profit to be slightly lower in 2024February 22, 2024 | markets.businessinsider.comHikma Pharma FY Profit IncreasesFebruary 1, 2024 | msn.comHikma Pharmaceuticals did not report suspicious opioid orders for 15 years, NC Attorney General Josh Stein saysFebruary 1, 2024 | marketwatch.comHikma Pharmaceuticals Agrees in Principle to Pay up to $115M in US Opioid SettlementFebruary 1, 2024 | finance.yahoo.comAd firm Publicis, drugmaker Hikma settle US opioid cases for $500 millionFebruary 1, 2024 | finance.yahoo.comUPDATE 1-Ad firm Publicis, drugmaker Hikma settle US opioid cases for $500 millionJanuary 29, 2024 | finance.yahoo.comHikma Pharmaceuticals PLC's (LON:HIK) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?October 5, 2023 | finance.yahoo.comThe one-year decline in earnings might be taking its toll on Hikma Pharmaceuticals (LON:HIK) shareholders as stock falls 3.3% over the past weekOctober 3, 2023 | finance.yahoo.comStocks Open Lower, Weighed Down by Rising Bond YieldsAugust 10, 2023 | finance.yahoo.comRakuten Medical and Hikma Sign Exclusive Licensing Agreement for Alluminox™ Platform Cancer Treatment in the Middle East and North AfricaAugust 9, 2023 | marketwatch.comHikma Appoints Bill Larkins as President of Injectables BusinessJuly 26, 2023 | finance.yahoo.comHikma Ventures invests in Octave Bioscience, a precision care platform for Multiple Sclerosis and other neurodegenerative diseasesMay 6, 2023 | msn.comSelling Hikma Pharmaceuticals After A 40% Share Price Gain In 7 MonthsApril 12, 2023 | lse.co.ukHikma Pharmaceutical appoints Injectables lead Mishlawi as new CEOApril 12, 2023 | nasdaq.comHikma Pharma Appoints Riad Mishlawi As CEO, Effective Sept. 1April 12, 2023 | marketwatch.comHikma Pharmaceuticals Appoints Riad Mishlawi CEOApril 12, 2023 | msn.comHikma Pharma names Mishlawi as next CEOApril 4, 2023 | finance.yahoo.comThose who invested in Hikma Pharmaceuticals (LON:HIK) five years ago are up 57%March 18, 2023 | marketwatch.comHikma Pharmaceuticals rises Thursday, still underperforms marketMarch 15, 2023 | marketwatch.comHikma Pharmaceuticals falls Monday, still outperforms marketMarch 9, 2023 | finance.yahoo.comHikma expands impact in Canada with launches of new sterile injectable medicinesSee More Headlines Receive HKMPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Ex-Dividend for 5/3 Dividend3/20/2024Dividend Payable5/03/2024Today5/17/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private households Sub-IndustryN/A Current SymbolOTCMKTS:HKMPF Previous SymbolOTC:HKMPF CUSIPN/A CIKN/A Webwww.hikma.com Phone442073992760Fax44-20-7399-2761Employees8,800Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.47 Current Ratio1.57 Quick Ratio0.90 Sales & Book Value Annual Sales$2.88 billion Price / Sales1.88 Cash Flow$3.33 per share Price / Cash Flow7.36 Book Value$10.03 per share Price / Book2.44Miscellaneous Outstanding Shares220,230,000Free FloatN/AMarket Cap$5.40 billion OptionableNot Optionable Beta0.51 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesEngineer Said Samih Taleb Darwazah (Age 67)Executive Chairman Comp: $2.8MMr. Riad Ali Mishlawi (Age 60)CEO & Director Comp: $1.1MMr. Mazen Samih Taleb Darwazah (Age 66)Executive Vice Chairman & President of MENA Comp: $2.3MMr. Khalid Waleed Hosny Al Nabilsi (Age 52)Chief Financial Officer Patricia BousfieldChief Information OfficerMr. Guy FeatherstoneAssociate Director of Investor RelationsMr. Samuel ParkGeneral CounselMr. Bassam Wael Rushdi Kanaan CFA (Age 59)CPA, Executive Vice President of Corporate Development and M&A Mr. Hussein Omar ArkhaghaChief People OfficerMs. Susan RingdalExecutive Vice President of Strategic Planning & Global AffairsMore ExecutivesKey CompetitorsAspen PharmacareOTCMKTS:APNHYSunny Optical Technology (Group)OTCMKTS:SNPTFOrion OyjOTCMKTS:ORINYSino BiopharmaceuticalOTCMKTS:SBMFFZealand Pharma A/SOTCMKTS:ZLDPFView All Competitors HKMPF Stock Analysis - Frequently Asked Questions Should I buy or sell Hikma Pharmaceuticals stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" HKMPF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HKMPF, but not buy additional shares or sell existing shares. View HKMPF analyst ratings or view top-rated stocks. How have HKMPF shares performed in 2024? Hikma Pharmaceuticals' stock was trading at $22.7850 at the beginning of the year. Since then, HKMPF shares have increased by 7.5% and is now trading at $24.50. View the best growth stocks for 2024 here. Are investors shorting Hikma Pharmaceuticals? Hikma Pharmaceuticals saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 1,849,700 shares, an increase of 6.2% from the April 15th total of 1,741,900 shares. Based on an average trading volume of 200 shares, the days-to-cover ratio is currently 9,248.5 days. View Hikma Pharmaceuticals' Short Interest. How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals? Hikma Pharmaceuticals declared a dividend on Wednesday, March 6th. Investors of record on Friday, March 22nd will be paid a dividend of $0.47 per share on Friday, May 3rd. The ex-dividend date of this dividend is Wednesday, March 20th. This is an increase from the stock's previous dividend of $0.25. Read our dividend analysis for HKMPF. Is Hikma Pharmaceuticals a good dividend stock? Hikma Pharmaceuticals (OTCMKTS:HKMPF) pays an annual dividend of $0.94 per share and currently has a dividend yield of 3.84%. Read our dividend analysis for HKMPF. How do I buy shares of Hikma Pharmaceuticals? Shares of HKMPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:HKMPF) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchDems have chosen Biden replacement?Paradigm PressHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportWhy Is Gold On a MASSIVE rally? Huge AlertsProtect Your Bank Account Before It’s Too LateWeiss RatingsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingA ‘DeFi Summer’ Projected!Crypto 101 MediaMissed NVDA? Buy this AI stock NOWChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hikma Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.